Lapatinib in Endocrine-Resistant Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.